Search 

Baxter Ventures is the strategic venture arm of Baxter International Inc. that was formed in 2011 and is based in Deerfield, Illinois. The firm is currently making equity investments out of a $200 Million fund with allocations generally falling in the $3-$5 million range. The firm is looking in invest in companies who have previously or are currently in the process of securing investment from other institutional investors. The firm is willing to look globally for investment opportunities and plans to make approximately 2 new investments over the next 6-9 months.

BIOARRAY is a biotech company located at the Science park in New Haven. BIOARRAY is customizing treatments for patients to cure breast cancer the first time. BIOARRAY’s lead breast cancer test has been shown to reduce ineffective treatments by over 50% in proof of concept studies. BIOARRAY is a recipient of Avon Foundation and Connecticut Innovations funds. BIOARRAY is a MassChallenge Accelerator Winner.

Bionure is a late-preclinical company focused at developing First-in-Class SGK agonists for the treatment of orphan ophthalmological diseases.

Bionure's main candidate is BN201, a small molecule, new chemical entity, first-in-class drug that promotes neuroprotection and remyelination by means of a novel MOA.

Our main therapeutic focus is Optic Neuritis (ON), an acute, inflammatory disease of the optic nerve that qualifies for orphan status. BN201 has been granted orphan designation for the treatment of ON and the patent has been granted.

Preclinical efficacy studies have been performed in several animal models and a pre-IND meeting has been held with the FDA to validate our preclinical and clinical development. 

BN201 is now through the regulatory toxicology studies to enable IND by Q2 2015.

BioScience Managers is a venture capital life science investment firm headquartered in Melbourne, Australia. The group makes equity investments from $3M-5M and anticipates about 6 new investments this year. BioScience Managers invests globally. 

BioScience Managers will invest in companies across the life science space, including therapeutics, diagnostics and medical technology. The group does not invest in service providers. BioScience Managers considers all subsectors and indications, including orphan indications. The group will consider technology either in or prepared for human clinical trials and is open to all classes of devices. BioScience Managers seeks investments in novel technology and is not looking to gain share of an existing market. 

Biosortia has opened the door to a new frontier of fascinating compounds that have the potential to materially impact the direction of various chronic diseases.  We are dedicated to discovering new chemical entities for the management of critical chronic disease states such as cancer, neuroscience, infectious disease, and inflammatory disorders to ultimately improve the lives of others.

Value Proposition

Pharma is looking for 3 key things:

1. Novel, never seen before, chemistry from new environments to fight chronic disease

2. Higher levels of potency (nano to Pico molar) to reduce the impact of side-effects

3. New mechanisms of action to fight chronic disease in new and more effective manner

It is well known that micro-organism consortia (not macro) are one of the most biologically active and chemically diverse plant/fungi that are rich in what we call “Defense Mechanism Chemistry”.  Defense Mechanism Chemistry is key in developing drugs for cancer, infectious disease and inflammation.  The problem is no one has been able to get access to this unique chemistry at scale and have the natural products expertise to identify the unique compounds…until now.  

We will provide Pharma with new compounds, rich in “Defense Mechanism Chemistry” on a routine basis that could shorten the discovery cycle by 2-3 years and reduce the overall cost.  

Best Regards,

Kurt Dieck

President and CEO

kdieck@biosortia.com

(614) 296-7076

BioTherapeutics Inc. (BTI) is a pre-clinical stage company developing novel small-molecule drugs to treat inflammation associated with autoimmune related disorders and type 2 diabetes (T2D). We have identified an orally-active, first-in-class top lead compound that targets a unique and novel MoA: the LANCL2 pathway. Our top lead compound has demonstrated extremely positive efficacy in mouse models of both IBD and T2D and our preliminary toxicology data has confirmed that is safe at a very high dose and as a multiple dose for 14 days.

We just closed a very well funded seed round (NIH, CIT Gap Funds, other investments) and we are now looking to raise from $3 to $5M to generate IND enabling data and start human trials.

Boehringer Ingelheim was founded in 1885 and is based in Ingelheim am Rhein Germany. The firm invests by means of in-licensing and acquisitions and is primarily focused on respiratory diseases cardiovascular diseases metabolic diseases oncology diseases of the central nervous system and immunology. Boehringer Ingelheim also invests in veterinary medicine.

Brace Pharmaceuticals is based in Rockville, MD, and is a strategic investment company formed by Brazil-based pharma company EMS S/A. Brace investment structure varies depending on a company’s development stage; for early-stage opportunities Brace typically makes equity investments and may syndicate with other investors, whereas for clinical-stage opportunities Brace is more likely to form strategic partnerships that involve rights to an asset. Brace is open to considering therapeutic opportunities globally, but only if the company is pursuing the US market.

Brace Pharmaceuticals invests in therapeutics; about 80% of the firm’s investments are in clinical-stage assets, with a preference for companies with some human proof-of-concept data; the remaining 20% of investments are made in preclinical opportunities. Drug-device combinations will also be considered, but Brace does not invest in diagnostics. The firm will invest in both small and large molecules, and has a strong preference for investing in orphan drugs and other niche disease areas. It is preferred that indications have validated clinical endpoints and can be studied using small trials. Indications that require large clinical trials, including as cardiovascular diseases and primary care indications (such as influenza) will not be considered.